Aligos Therapeutics (NASDAQ:ALGS) Shares Down 8.4% – Time to Sell?

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s share price traded down 8.4% on Monday . The stock traded as low as $6.98 and last traded at $6.98. 56,506 shares were traded during mid-day trading, an increase of 87% from the average session volume of 30,152 shares. The stock had previously closed at $7.62.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Friday, September 20th.

Aligos Therapeutics Stock Performance

The business’s 50 day moving average price is $11.65 and its 200-day moving average price is $14.59. The firm has a market capitalization of $564.74 million, a PE ratio of -5.64 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The firm had revenue of $1.06 million for the quarter. During the same quarter in the prior year, the firm posted ($10.75) EPS. As a group, analysts anticipate that Aligos Therapeutics, Inc. will post -8.2 earnings per share for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ALGS. Armistice Capital LLC increased its position in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after acquiring an additional 363,000 shares during the period. Acadian Asset Management LLC lifted its stake in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after acquiring an additional 171,490 shares during the last quarter. Finally, Opaleye Management Inc. grew its holdings in Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after acquiring an additional 333,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).